PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan - Rising private expenditure, Ageing societies and increasing health awareness propel IVD market in Central and Eastern Europe - DrugDiscovery.Frost.com
IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/08/01 - Rising private expenditure, Ageing societies and increasing health awareness propel IVD market in Central and Eastern Europe - DrugDiscovery.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Scarcity of financial resources available for in vitro diagnostics (IVD) is the key challenge for the market across Central and Eastern Europe (CEE). At the same time, ageing societies, growing health awareness and increasing affluence are boosting demand for IVD testing, including technologically advanced molecular diagnostic testing.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Strategic Analysis of CEE IVD Market, finds that the market earned revenues of $991.4 million in 2010 and estimates this to reach $1,880.2 million in 2017. The study covers clinical chemistry, hematology, microbiology, point-of-care testing, self-monitoring of blood glucose, molecular diagnostics and immunodiagnostics products in the Czech Republic, Hungary, Poland and Russia.

"The rising demand for private testing is a result of the poor efficiency and quality of public laboratories as well as insufficient public funding for IVD in the CEE region," notes Frost & Sullivan Research Analyst Dominika Grzywinska. "This factor is especially visible in Russia, where paid diagnostic services are booming."

In Russia, receiving services financed by the compulsory health insurance (OMS) is very difficult. Public laboratories face several problems, such as poor quality of service, insufficient supply of diagnostic equipment and long waiting times. In other CEE countries, the key reason for people opting for private testing is insufficient financing from health insurance.

Financial resources available for IVD services are insufficient. The money spent on IVD in CEE countries constituted between 1 and 2 per cent of total healthcare expenditure in 2010.

In the Czech Republic, healthcare funding is being reduced, which has limited the resources for IVD. In Poland, there is an absence of control mechanisms on how much should be spent on IVD. In Russia, limited financing has resulted in long waiting lines and poor quality of publicly provisioned laboratory diagnostic services. In Hungary, volume limits were introduced for laboratory services financing in 2006.

"Increasing affluence in these countries, coupled with growing health awareness has, therefore, resulted in higher private expenditure on laboratory diagnostics," remarks Grzywinska.

The lack of funding for IVD has resulted in slow technology uptake and high price sensitivity across CEE. Another challenge relates to the high fragmentation of laboratories, which decreases their efficiency.

Research shows that countries in CEE do not fall behind the developed countries in terms of technologies. New solutions are introduced practically at the same time as in western countries.

"The key difference between those two regions is that the commercial uptake of technologies is much slower in CEE, due to the scarcity of financial resources available for IVD," elaborates Grzywinska. "As a result, even though a technology is available in the country, it may still not be used in routine testing and not be reimbursed."

Furthermore, low public expenditure on IVD has led to increasing price pressures. Price remains the key decision-making factor for end users and this situation is likely to persist throughout 2011-2017.

End users of the CEE IVD market are predominantly small laboratories performing a low number of tests annually. They do not purchase large amounts of reagents, and therefore have to pay retail prices, instead of lower, wholesale prices. In this case, one dollar spent on diagnostics in CEE is less efficient than one dollar spent on diagnostics in western European countries.

"Although new technologies are present in the CEE countries, lack of funding inhibits their commercialisation," states Grzywinska. "Delivering product of top quality at affordable prices is the key to achieving success."

Increasing public financing for IVD would be the fastest and most effective means to improve market prospects. However, in the face of cost mitigation efforts undertaken by governments, this scenario seems unlikely. Therefore, manufacturers should be aware of end users' high price sensitivity and try to balance product performance with cost.

If you are interested in more information on this study, please send an email with your contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]frost.com.

Strategic Analysis of CEE IVD Market is part of the Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: Eastern European IVD Market, Western European IVD Markets and Strategic Analysis of the Global In Vitro Diagnostics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Strategic Analysis of CEE IVD Market / M693

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IVD Market Participants Need to Balance Price with Performance to Boost Sales Says Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Janique Morvan 
+33 (0)1 42 81 20 37 janique.morvan[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)